Review



plbd1 mrna expression data  (Human Protein Atlas)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Human Protein Atlas plbd1 mrna expression data
    Plbd1 Mrna Expression Data, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plbd1 mrna expression data/product/Human Protein Atlas
    Average 90 stars, based on 1 article reviews
    plbd1 mrna expression data - by Bioz Stars, 2026-02
    90/100 stars

    Images



    Similar Products

    mrna expression data  (Illumina Inc)
    90
    Illumina Inc mrna expression data
    Mrna Expression Data, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mrna expression data/product/Illumina Inc
    Average 90 stars, based on 1 article reviews
    mrna expression data - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    hiseq mrna expression data  (Illumina Inc)
    90
    Illumina Inc hiseq mrna expression data
    Hiseq Mrna Expression Data, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hiseq mrna expression data/product/Illumina Inc
    Average 90 stars, based on 1 article reviews
    hiseq mrna expression data - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    plbd1 mrna expression data  (Human Protein Atlas)
    90
    Human Protein Atlas plbd1 mrna expression data
    Plbd1 Mrna Expression Data, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/plbd1 mrna expression data/product/Human Protein Atlas
    Average 90 stars, based on 1 article reviews
    plbd1 mrna expression data - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    mrna expression data  (Human Protein Atlas)
    90
    Human Protein Atlas mrna expression data
    Mrna Expression Data, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mrna expression data/product/Human Protein Atlas
    Average 90 stars, based on 1 article reviews
    mrna expression data - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    bulk mrna expression data  (Beijing Tiantan Biological)
    90
    Beijing Tiantan Biological bulk mrna expression data
    (A) mRNAsi <t>(mRNA</t> <t>expression-based</t> stemness index) comparison between high and low TMErisk groups. The high TMErisk group shows significantly lower mRNAsi (p = 0.026), indicating lower tumor cell stemness. (B) Immune cell infiltration analysis between high and low TMErisk groups. Significant differences are observed in various immune cell types, including naive B cells, memory B cells, plasma cells, CD8+ T cells, naive CD4+ T cells, and regulatory T cells (Tregs), with higher TMErisk scores associated with distinct immune cell infiltration patterns (*p < 0.05, **p < 0.01). (C) Enrichment analysis of gene function set in high-risk group based on GO database. (D) Enrichment analysis of gene function set in low-risk group based on GO database. (E) Enrichment analysis of gene function set in high-risk group based on KEGG database. (F) Enrichment analysis of gene function set in high-risk group based on KEGG database. (G) Correlation between TMErisk scores and immune phenotype scores (IPS) across different medulloblastoma subtypes. A significant negative correlation is observed in the G3 subtype (R = -0.31, p = 0.0081), indicating lower immune response in patients with higher TMErisk scores. (H) Correlation between TMErisk scores and tumor mutational burden (TMB) across different medulloblastoma subtypes. A significant positive correlation is observed in the G4 subtype (R = -0.44, p = 0.012), suggesting patients with higher TMErisk scores have lower TMB. (I) Drug sensitivity analysis showing significant differences in sensitivity to various cytotoxic and targeted therapy drugs between high and low TMErisk groups. High TMErisk scores are associated with reduced sensitivity to drugs like Camptothecin, Cytarabine, Navitoclax, Vorinostat, and Wee1 Inhibitor. ***: P<0.001, ns: Not Significant
    Bulk Mrna Expression Data, supplied by Beijing Tiantan Biological, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bulk mrna expression data/product/Beijing Tiantan Biological
    Average 90 stars, based on 1 article reviews
    bulk mrna expression data - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    tcga mrna expression data  (Santa Cruz Biotechnology)
    90
    Santa Cruz Biotechnology tcga mrna expression data
    (A) mRNAsi <t>(mRNA</t> <t>expression-based</t> stemness index) comparison between high and low TMErisk groups. The high TMErisk group shows significantly lower mRNAsi (p = 0.026), indicating lower tumor cell stemness. (B) Immune cell infiltration analysis between high and low TMErisk groups. Significant differences are observed in various immune cell types, including naive B cells, memory B cells, plasma cells, CD8+ T cells, naive CD4+ T cells, and regulatory T cells (Tregs), with higher TMErisk scores associated with distinct immune cell infiltration patterns (*p < 0.05, **p < 0.01). (C) Enrichment analysis of gene function set in high-risk group based on GO database. (D) Enrichment analysis of gene function set in low-risk group based on GO database. (E) Enrichment analysis of gene function set in high-risk group based on KEGG database. (F) Enrichment analysis of gene function set in high-risk group based on KEGG database. (G) Correlation between TMErisk scores and immune phenotype scores (IPS) across different medulloblastoma subtypes. A significant negative correlation is observed in the G3 subtype (R = -0.31, p = 0.0081), indicating lower immune response in patients with higher TMErisk scores. (H) Correlation between TMErisk scores and tumor mutational burden (TMB) across different medulloblastoma subtypes. A significant positive correlation is observed in the G4 subtype (R = -0.44, p = 0.012), suggesting patients with higher TMErisk scores have lower TMB. (I) Drug sensitivity analysis showing significant differences in sensitivity to various cytotoxic and targeted therapy drugs between high and low TMErisk groups. High TMErisk scores are associated with reduced sensitivity to drugs like Camptothecin, Cytarabine, Navitoclax, Vorinostat, and Wee1 Inhibitor. ***: P<0.001, ns: Not Significant
    Tcga Mrna Expression Data, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tcga mrna expression data/product/Santa Cruz Biotechnology
    Average 90 stars, based on 1 article reviews
    tcga mrna expression data - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    mrna expression data rsem  (Illumina Inc)
    90
    Illumina Inc mrna expression data rsem
    (A) mRNAsi <t>(mRNA</t> <t>expression-based</t> stemness index) comparison between high and low TMErisk groups. The high TMErisk group shows significantly lower mRNAsi (p = 0.026), indicating lower tumor cell stemness. (B) Immune cell infiltration analysis between high and low TMErisk groups. Significant differences are observed in various immune cell types, including naive B cells, memory B cells, plasma cells, CD8+ T cells, naive CD4+ T cells, and regulatory T cells (Tregs), with higher TMErisk scores associated with distinct immune cell infiltration patterns (*p < 0.05, **p < 0.01). (C) Enrichment analysis of gene function set in high-risk group based on GO database. (D) Enrichment analysis of gene function set in low-risk group based on GO database. (E) Enrichment analysis of gene function set in high-risk group based on KEGG database. (F) Enrichment analysis of gene function set in high-risk group based on KEGG database. (G) Correlation between TMErisk scores and immune phenotype scores (IPS) across different medulloblastoma subtypes. A significant negative correlation is observed in the G3 subtype (R = -0.31, p = 0.0081), indicating lower immune response in patients with higher TMErisk scores. (H) Correlation between TMErisk scores and tumor mutational burden (TMB) across different medulloblastoma subtypes. A significant positive correlation is observed in the G4 subtype (R = -0.44, p = 0.012), suggesting patients with higher TMErisk scores have lower TMB. (I) Drug sensitivity analysis showing significant differences in sensitivity to various cytotoxic and targeted therapy drugs between high and low TMErisk groups. High TMErisk scores are associated with reduced sensitivity to drugs like Camptothecin, Cytarabine, Navitoclax, Vorinostat, and Wee1 Inhibitor. ***: P<0.001, ns: Not Significant
    Mrna Expression Data Rsem, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mrna expression data rsem/product/Illumina Inc
    Average 90 stars, based on 1 article reviews
    mrna expression data rsem - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) mRNAsi (mRNA expression-based stemness index) comparison between high and low TMErisk groups. The high TMErisk group shows significantly lower mRNAsi (p = 0.026), indicating lower tumor cell stemness. (B) Immune cell infiltration analysis between high and low TMErisk groups. Significant differences are observed in various immune cell types, including naive B cells, memory B cells, plasma cells, CD8+ T cells, naive CD4+ T cells, and regulatory T cells (Tregs), with higher TMErisk scores associated with distinct immune cell infiltration patterns (*p < 0.05, **p < 0.01). (C) Enrichment analysis of gene function set in high-risk group based on GO database. (D) Enrichment analysis of gene function set in low-risk group based on GO database. (E) Enrichment analysis of gene function set in high-risk group based on KEGG database. (F) Enrichment analysis of gene function set in high-risk group based on KEGG database. (G) Correlation between TMErisk scores and immune phenotype scores (IPS) across different medulloblastoma subtypes. A significant negative correlation is observed in the G3 subtype (R = -0.31, p = 0.0081), indicating lower immune response in patients with higher TMErisk scores. (H) Correlation between TMErisk scores and tumor mutational burden (TMB) across different medulloblastoma subtypes. A significant positive correlation is observed in the G4 subtype (R = -0.44, p = 0.012), suggesting patients with higher TMErisk scores have lower TMB. (I) Drug sensitivity analysis showing significant differences in sensitivity to various cytotoxic and targeted therapy drugs between high and low TMErisk groups. High TMErisk scores are associated with reduced sensitivity to drugs like Camptothecin, Cytarabine, Navitoclax, Vorinostat, and Wee1 Inhibitor. ***: P<0.001, ns: Not Significant

    Journal: Frontiers in Oncology

    Article Title: Multi-omics approach reveals the impact of prognosis model-related genes on the tumor microenvironment in medulloblastoma

    doi: 10.3389/fonc.2025.1477617

    Figure Lengend Snippet: (A) mRNAsi (mRNA expression-based stemness index) comparison between high and low TMErisk groups. The high TMErisk group shows significantly lower mRNAsi (p = 0.026), indicating lower tumor cell stemness. (B) Immune cell infiltration analysis between high and low TMErisk groups. Significant differences are observed in various immune cell types, including naive B cells, memory B cells, plasma cells, CD8+ T cells, naive CD4+ T cells, and regulatory T cells (Tregs), with higher TMErisk scores associated with distinct immune cell infiltration patterns (*p < 0.05, **p < 0.01). (C) Enrichment analysis of gene function set in high-risk group based on GO database. (D) Enrichment analysis of gene function set in low-risk group based on GO database. (E) Enrichment analysis of gene function set in high-risk group based on KEGG database. (F) Enrichment analysis of gene function set in high-risk group based on KEGG database. (G) Correlation between TMErisk scores and immune phenotype scores (IPS) across different medulloblastoma subtypes. A significant negative correlation is observed in the G3 subtype (R = -0.31, p = 0.0081), indicating lower immune response in patients with higher TMErisk scores. (H) Correlation between TMErisk scores and tumor mutational burden (TMB) across different medulloblastoma subtypes. A significant positive correlation is observed in the G4 subtype (R = -0.44, p = 0.012), suggesting patients with higher TMErisk scores have lower TMB. (I) Drug sensitivity analysis showing significant differences in sensitivity to various cytotoxic and targeted therapy drugs between high and low TMErisk groups. High TMErisk scores are associated with reduced sensitivity to drugs like Camptothecin, Cytarabine, Navitoclax, Vorinostat, and Wee1 Inhibitor. ***: P<0.001, ns: Not Significant

    Article Snippet: The bulk mRNA expression data of 322 MB patients from Beijing Tiantan Hospital were used as the training cohort (240 patients with complete follow-up data available).

    Techniques: Expressing, Comparison, Clinical Proteomics